This form of “passive” APC targeting was further evidenced by our own observation that noninfectious LVs were able to induce a similar therapeutic benefit in the E.G7-OVA tumor model as the APC targeted LVs after their intranodal delivery [45]. The gene discussed is APC; the disease is neoplasm.